Prediction of early responses to dupilumab treatment in patients with moderate-to-severe atopic dermatitis by a machine learning model integrating clinical characteristics and serum biomarkers

Hong Huang; Mengdi Xu; Weijia Zhao

doi:10.5114/ada.2026.162843

Full text

3/2026 vol. 43

Original paper

Prediction of early responses to dupilumab treatment in patients with moderate-to-severe atopic dermatitis by a machine learning model integrating clinical characteristics and serum biomarkers

Hong Huang ¹

,

Mengdi Xu ¹

,

Weijia Zhao ¹

First Affiliated Hospital of Kunming Medical University, Kunming, China

Adv Dermatol Allergol 2026; XLIII (3): 280–287

DOI: https://doi.org/10.5114/ada.2026.162843

Data publikacji online: 2026/07/19

Article file

PDIA Prediction.pdf

AMA

Huang H, Xu M, Zhao W. Prediction of early responses to dupilumab treatment in patients with moderate-to-severe atopic dermatitis by a machine learning model integrating clinical characteristics and serum biomarkers. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2026;43(3):280-287. doi:10.5114/ada.2026.162843.

APA

Huang, H., Xu, M., & Zhao, W. (2026). Prediction of early responses to dupilumab treatment in patients with moderate-to-severe atopic dermatitis by a machine learning model integrating clinical characteristics and serum biomarkers. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 43(3), 280-287. https://doi.org/10.5114/ada.2026.162843

Chicago

Huang, Hong, Mengdi Xu, and Weijia Zhao. 2026. "Prediction of early responses to dupilumab treatment in patients with moderate-to-severe atopic dermatitis by a machine learning model integrating clinical characteristics and serum biomarkers". Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii 43 (3): 280-287. doi:10.5114/ada.2026.162843.

Harvard

Huang, H., Xu, M., and Zhao, W. (2026). Prediction of early responses to dupilumab treatment in patients with moderate-to-severe atopic dermatitis by a machine learning model integrating clinical characteristics and serum biomarkers. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 43(3), pp.280-287. https://doi.org/10.5114/ada.2026.162843

MLA

Huang, Hong et al. "Prediction of early responses to dupilumab treatment in patients with moderate-to-severe atopic dermatitis by a machine learning model integrating clinical characteristics and serum biomarkers." Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, vol. 43, no. 3, 2026, pp. 280-287. doi:10.5114/ada.2026.162843.

Vancouver

Huang H, Xu M, Zhao W. Prediction of early responses to dupilumab treatment in patients with moderate-to-severe atopic dermatitis by a machine learning model integrating clinical characteristics and serum biomarkers. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2026;43(3):280-287. doi:10.5114/ada.2026.162843.

Gatmaitan JG, Lee JH. Challenges and future trends in atopic dermatitis. Int J Mol Sci 2023; 24: 11380.
Royeck S. Biologics in the treatment of atopic dermatitis: approved active substances and monoclonal antibodies in advanced clinical trials. Allergo J Int 2025; 34: 159-66.
Chu CY, Chan Y, Wananukul S, et al. Quality of life and burden of moderate-to-severe atopic dermatitis in adult patients within the Asia-Pacific region: a cross-sectional survey. Dermatol Ther (Heidelb) 2024; 14: 2479-93.
Beck LA, Bissonnette R, Deleuran M, et al. Dupilumab in adults with moderate to severe atopic dermatitis: a 5-year open-label extension study. JAMA Dermatol 2024; 160: 805-12.
Londoño J, Perez L, Moreno S, et al. Effectiveness and safety of dupilumab in adults with moderate and severe atopic dermatitis: real-life experience. World Allergy Organ J 2023; 16: 100763.
Orayj K, Samuel VP, Saleem S, et al. Immunoassay-based biomarkers in atopic dermatitis. Clin Chim Acta 2026; 579: 120634.
Bieber T. The paradigm shift in drug development for atopic dermatitis: addressing the variables of the equation leading to disease modification. Ann Allergy Asthma Immunol 2025; 134: 144-50.
Ravindran S, Kaleem Ullah M, Karnik M, et al. Unsupervised phenotyping of asthma: integrating serum periostin with clinical and inflammatory profiles. Diagnostics 2025; 15: 3028.
Nakahara T, Izuhara K, Onozuka D, et al. Exploring biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab (B-PAD study). Clin Exp Allergy 2023; 53: 233-8.
Collins GS, Reitsma JB, Altman DG, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ 2015; 350: g7594.
Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980; 92: 44-7.
Wollenberg A, Christen-Zäch S, Taieb A, et al. ETFAD/EADV eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol 2020; 34: 2717-44.
Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375: 2335-48.
Schmitt J, Langan S, Deckert S, et al. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol 2013; 132: 1337-47.
Nunomura S, Uta D, Kitajima I, et al. Periostin activates distinct modules of inflammation and itching downstream of the type 2 inflammation pathway. Cell Rep 2023; 42: 111933.
Tran NQV, Kobayashi Y, Nakamura Y, et al. Transcriptomic evidence for T cell-fibroblast-keratinocyte axis via IL-13-periostin-integrin in atopic dermatitis. Allergy 2024; 79: 3521-5.
Maintz L, Welchowski T, Herrmann N, et al. IL-13, periostin and dipeptidyl-peptidase-4 reveal endotype-phenotype associations in atopic dermatitis. Allergy 2023; 78: e15647.
Starrenburg ME, Bel Imam M, Lopez JF, et al. Dupilumab treatment decreases MBC2s, correlating with reduced IgE levels in pediatric atopic dermatitis. J Allergy Clin Immunol 2024; 154: 1333-8.e4.
Dekkers C, van der Wal MM, van den Noort L, et al. IgE levels in patients with atopic dermatitis steadily decrease during treatment with dupilumab regardless of dose interval. Clin Exp Allergy 2023; 53: 1222-5.
Baldo DC, Romaldini JG, Pizzichini MMM, et al. Periostin as an important biomarker of inflammatory phenotype T2 in Brazilian asthma patients. J Bras Pneumol 2023; 49: e20220040.
Hamilton JD, Harel S, Swanson BN, et al. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin Exp Allergy 2021; 51: 915-31.
Hijnen D, Olydam J. Prediction of response to dupilumab treatment. Br J Dermatol 2023; 188: e41.
Chiricozzi A, Levi A, Palladino C, et al. Enabling precision medicine with biomarkers of response to treatment in atopic dermatitis: where are we now? Front Med (Lausanne) 2025; 12: 1574697.

Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

SUBMIT YOUR PAPER

Share

Indexed in

Integrated with

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications